Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer

Bevacizumab combined with cytotoxic chemotherapy is the backbone of metastatic colorectal cancer (mCRC) therapy; however, its treatment efficacy is hampered by therapeutic resistance. Therefore, understanding the mechanisms underlying bevacizumab resistance is crucial to increasing the therapeutic e...

Descripción completa

Detalles Bibliográficos
Autores principales: Makondi, Precious Takondwa, Lee, Chia-Hwa, Huang, Chien-Yu, Chu, Chi-Ming, Chang, Yu-Jia, Wei, Po-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771567/
https://www.ncbi.nlm.nih.gov/pubmed/29342159
http://dx.doi.org/10.1371/journal.pone.0189582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771567/
https://www.ncbi.nlm.nih.gov/pubmed/29342159
http://dx.doi.org/10.1371/journal.pone.0189582

Ejemplares similares